Clinical Trial Update: Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM) [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and pharmacokinetics of Sialic Acid Tables in patients with Hereditary inclusion body myopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Inclusion Body Myopathy

Drugs mentioned

• Sialic Acid Tables (sialic acid)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Hereditary Inclusion Body Myopathy (HIBM) | Phase 1 | Status: COMPLETED